Trial Profile
Double-masked, Comparison Study of DE-114A Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Epinastine (Primary)
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Santen Pharmaceutical
- 16 Aug 2018 Status changed from recruiting to completed.
- 17 May 2017 New trial record